Table 1.
Selected clinical trials targeted in CXCL8-CXCR1/2 axis.
| Drug (Manufacturer) | Target | Therapeutic Combinations | Cancer Type | Phase | Clinical Trials |
Recruitment Status |
|---|---|---|---|---|---|---|
| SX-682 (Syntrix Biosystems, Inc.) | CXCR1/2 | Pembrolizumab (anti-PD-1) | Metastatic Melanoma | Phase I | NCT03161431 | Recruiting |
| Nivolumab (anti-PD-1) | Metastatic Colorectal Carcinoma | Phase Ib/II | NCT04599140 | Recruiting | ||
| Nivolumab (anti-PD-1) | Pancreatic Cancer | Phase I | NCT04477343 | Recruiting | ||
| Bintrafusp alfa (anti-PD-L1/TGF-β) CV301 (cancer vaccine) |
Advanced Solid Tumors | Phase I | NCT04574583 | Active, not recruiting | ||
| AZD5069 (AstraZeneca) | CXCR2 | Durvalumab (anti-PD-L1) | Advanced Solid Tumors | Phase Ib/II | NCT02499328 | Active, not recruiting |
| Durvalumab (anti-PD-L1) | Metastatic Pancreatic Ductal Adenocarcinoma | Phase II | NCT02583477 | Completed | ||
| Navarixin (Merck Sharp & Dohme Corp.) | CXCR1/2 | Pembrolizumab (anti-PD-1) | Advanced Solid Tumors | Phase II | NCT03473925 | Completed |
| HuMax-IL8 (Bristol-Myers Squiibb) | CXCL8 | Nivolumab (anti-PD-1) | Head and Neck Squamous Cell Carcinoma | Phase II | NCT04848116 | Recruiting |
| Nivolumab (anti-PD-1) | Prostate Cancer | Phase Ib/II | NCT03689699 | Recruiting | ||
| Nivolumab (anti-PD-1) | Pancreatic Cancer | Phase II | NCT02451982 | Recruiting | ||
| Nivolumab (anti-PD-1) | Hepatocellular Carcinoma | Phase II | NCT04050462 | Recruiting | ||
| Nivolumab (anti-PD-1) | Advanced Cancers | Phase I/II | NCT03400332 | Recruiting | ||
| Nivolumab (anti-PD-1) | Non-small Cell Lung Cancer | Phase II | NCT04123379 | Recruiting |